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Effect of sodium hyaluronate added to topical
corticosteroids in chronic rhinosinusitis with nasal polyposis
Elena Cantone, M.D., Ph.D., and Maurizio Iengo, M.D.
ABSTRACT
Background: Available medical treatments for chronic rhinosinusitis (CRS) with nasal polyposis (CRSwNP) comprise systemic and topical therapies.
Although topical corticosteroids are effective in the treatment of CRS, they are not completely devoid of adverse effects. Thus, care has to be taken when
long-term treatments are prescribed. There is recent evidence that sodium hyaluronate (SH), the major component of many extracellular matrices, promotes
tissue healing, including activation and moderation of the inflammatory responses, cell proliferation, migration, and angiogenesis.
Objective: The aim of the study was to evaluate clinical outcomes and quality of life in two groups of patients with CRSwNP treated with topical
corticosteroids alone or in combination with 9 mg of high-molecular-weight SH.
Methods: The impact of treatments was determined by using nasal endoscopy and validated quality of life questionnaires (Short Form-36, 22-item
Sino-Nasal Outcome Test, visual analog scale [VAS]). Eighty subjects who had CRS with grade IV nasal polyposis: 40 diagnosed with allergic rhinitis (AR)
and 40 with non–allergic-eosinophilic rhinitis (NARES) based on skin-prick test and nasal cytology results, were divided in two groups. Group I comprised
40 subjects (20 AR and 20 NARES), who received mometasone furoate plus SH; group II comprised 40 subjects (20 AR and 20 NARES), who received
mometasone furoate plus saline solution alone. All the patients were followed up for 3 months.
Results: At baseline, no statistically significant differences were observed between the groups and the VAS score showed a moderate-to-severe degree of
disease. After treatments, Lund and Kennedy, Short Form-36, 22-item Sino-Nasal Outcome Test, and VAS scores were statistically significant in both groups
but slightly in favor of the group I and in the subjects with allergic CRSwNP.
Conclusion: Analysis of our data indicated that an SH supplement to standard corticosteroid seems to play an important role in improving the severity
of symptoms, the endoscopic appearance, and discomfort associated with CRSwNP. This effect seems to be strongest in patients with allergic CRSwNP.
(Am J Rhinol Allergy 30, 340–343, 2016; doi: 10.2500/ajra.2016.30.4344)
Chronic rhinosinusitis (CRS) with nasal polyposis (CRSwNP) af-fects 0.5–4% of the world population1–3 and is associated with
reduction of quality of life (QoL).4 The available medical treatments
for CRSwNP comprise systemic and topical therapies,5–8 but, for
patients with medically resistant CRSwNP, the surgical approach
represents the treatment of choice.5,9 However, it is well known that
both medical and surgical therapeutic strategies have high rates of
recurrence as the result of severe inflammatory reactions during the
mucosal healing period.10 Recently, there is mounting evidence that
sodium hyaluronate (SH), the major component of many extracellular
matrices, including those in respiratory epithelial cells and gland
serous cells of the nasal and trachea-bronchial mucosa, serves impor-
tant biologic roles beyond its generally accepted function as a struc-
tural component of interstitial and connective tissues.1
Because of its biologic properties, SH has several clinical applica-
tions, such as esthetic surgery, dermatology, orthopedics, and oph-
thalmology.11 Despite such a wide use, only a few studies assessed the
effects of SH on chronic or recurrent upper respiratory tract infec-
tions.1,3,4,12–14 Most of them provided evidence that SH is beneficial in
improving clinical and laboratory outcomes in affected children and
adults.1,3,4,12–14 In this regard, SH has been shown to promote wound
healing, repair mucosal surfaces, and cell motility.4,12,15 Particularly,
results of a previous research indicated that topical application of SH
significantly improves the healing process of the nasal mucosa and
prevents extensive crust formation, and eventually leads to the recov-
ery of smell parameters and cooling sensation.14 Results of a prospec-
tive randomized controlled trial indicated that a new absorbable SH
hydrogel, similar to a nasal dressing or packing after functional
endoscopic sinus surgery, promotes the postoperative reepitheliza-
tion process and reduces the presence of synechia, edema, crust, and
mild mucopurulent drainage.16
Furthermore, SH, in association with intranasal corticosteroid and
systemic antihistamine, reduces the neutrophil count shown on nasal
cytology in patients with allergic rhinitis (AR) and non-AR and
improves several clinical and endoscopic parameters.13 Although
evidence on the effectiveness of SH on postoperative care after
functional endoscopic sinus surgery is currently available,1 there
remains a dearth of evidence that evaluated its actual impact as
enhancer of intranasal corticosteroid on the CRSwNP and QoL of
affected patients. The aim of the study was to evaluate clinical and
QoL outcomes in two groups of patients with CRSwNP treated
with intranasal corticosteroids alone or in combination with 9 mg
of high-molecular-weight SH. In addition, we evaluated the effect
of SH as adjuvant therapy to intranasal corticosteroid on CRSwNP
with AR or with non-AR with eosinophils (NARES), with partic-
ular regard to the QoL.
METHODS
This double-blind study was carried out from October 2013 to April
2015 at the Ear Nose and Throat (ENT) section of the University of
Naples, “Federico II.” The patients were sequentially enrolled in the
study until reaching the planned sample size of 80 patients (mean
[standard deviation] age, 56.3  5.4 years) with CRSwNP. To exclude
sex-related interference reported in the literature, which revealed that
women have more severe disease than do men,17 we recruited 40 men
and 40 women; whereas, to evaluate the efficacy of SH in both
subjects with allergy and subjects without allergy, we recruited 40
subjects with positive skin-prick test results and 40 with negative
skin-prick test results and eosinophilic infiltration at rhinocytogram.
The diagnosis of CRSwNP was based on the European Position
Paper on Rhinosinusitis and Nasal Polyps diagnostic criteria.9 and
confirmed by nasal endoscopy and computed tomography scans with
axial, coronal, and sagittal images. Nasal endoscopy with a 4-mm, 30°,
rigid endoscope (Storz, Tuttlingen, Germany) was performed by an
experienced otolaryngologist (E.C.) blinded to patients’ clinical and
From the Department of Neuroscience, Ear Nose and Throat Section, Federico II
University, Naples, Italy
The authors have no conflicts of interest to declare pertaining to this article
No external funding sources reported
Address correspondence to Elena Cantone, M.D., Viale della Libertà, 75 CAP 81030
Lusciano, Italy
E-mail address: elenacantone@libero.it
Published online June 2, 2016
Copyright © 2016, OceanSide Publications, Inc., U.S.A.
340 September–October 2016, Vol. 30, No. 5
DO
 NO
T C
OP
Y
Delivered by Ingenta to: Universita degli Studi di Napoli  IP: 143.225.105.59 On: Tue, 12 Sep 2017 11:17:39
Copyright (c) Oceanside Publications, Inc. All rights reserved.
For permission to copy go to https://www.oceansidepubl.com/permission.htm
therapeutic data, before and after treatment, without decongestant or
local anesthesia and was scored as previously described by Lund and
Kennedy18 (score range, 0–20). The presence of residual polyps,
edema, discharge, scarring, and crusting of both nasal cavities was
scored from 0 to 2 as follows: absence of polyps (0), the presence of
polyps confined to the middle meatus (1), presence of polyps beyond
the middle meatus (2); no discharge (0), clear and thin discharge (1),
thick and purulent discharge (2); no edema or scarring or crusting (0),
mild (1), and severe (2).18
Computed tomographies performed only at baseline were scored
for both sinonasal sides as previously described by Lund and Mac-
kay19 (score range, 0–24). The Lund-Mackay scoring system quantifies
the severity of image opacification, no (0), partial (1), or complete
opacification (2), in the maxillary, ethmoidal, sphenoidal, osteomeatal
complex, and frontal sinuses.19
To characterize the allergic status, a skin-prick test and nasal cytol-
ogy were performed. For the nasal cytology, scraping of the nasal
mucosa was collected from the middle portion of the inferior turbi-
nate through anterior rhinoscopy by using a Nasal Scraping cytology
curette (IR Medical, Lugo, Italy). Samples were placed on a glass
slide, fixed by air-drying, stained according to the May-Gru¨nwald-
Giemsa method, and then observed by optical microscopy.4,13 For the
rhinocytogram analysis, 50 microscopic fields were read at a magni-
fication of 1000 to assess the presence of normal and abnormal
cellular elements or other pathologic microscopic features. The cell
count was carried out by a semiquantitative grading system, as pro-
posed by Meltzer and Jalowayski.20 We performed the nasal cytolog-
ical assessment evaluating the presence and the number of eosino-
phils.
In brief, we enrolled 40 subjects with positive skin-prick test results
and 40 with negative skin-prick test results and eosinophilic infiltra-
tion at rhinocytogram 20%. Patients with systemic diseases, acetyl-
salicylic acid sensitivity, cystic fibrosis, or primitive ciliary dyskinesia,
or with a history of interventions were excluded from the study as
well as subjects with other forms of non-AR: non-AR infiltrated by
mast cells, by eosinophils and mast cells, and by neutrophils. Subjects
who were being treated with antibiotics, steroids, antihistamines, and
local vasoconstrictive decongestants 3 months before were also ex-
cluded.
All the participants gave their informed consent to participate in
the study, which was fully approved by the board of medical ethics of
the University of Naples, “Federico II.” Recruited patients were al-
ternately assigned to two intervention groups and given the treat-
ment. The investigational arm (group I) comprised 40 subjects (20
men and 20 women; 20 with AR and 20 with NARES), and the control
arm (group II) comprised 40 subjects (20 men and 20 women; 20 with
AR and 20 with NARES). Group I received 200 g of mometasone
furoate nasal spray once a day for 3 months and 9 mg (3 mL) of
high-molecular-weight SH (Yabro; IBSA, Lugano, Switzerland) plus
saline solution (2 mL of sodium chloride 0.9%) administered twice a
day for 15 consecutive days per month for 3 consecutive months by
using a nebulizer ampoule for nasal douche. This device produces
particles of 10 m and acts only on the upper airways over a time
of 60 to 90 seconds for each application.1 Group II received 200 g of
mometasone furoate nasal spray and saline solution (5 mL of sodium
chloride 0.9%) alone, administered by using a nebulizer ampoule for
nasal douche according to the same protocol as group I. All the
patients were followed up for 3 months.
To assess therapeutic outcomes and QoL, both groups were asked
to answer three questionnaires. The first was the Italian Short
Form-36 (SF-36) questionnaire.1 This questionnaire, which measures
patients’ general health status, contains 36 questions that refer to eight
health concepts grouped into subgroups (physical functioning, phys-
ical role functioning, bodily pain, general health, vitality, social role
functioning, emotional role functioning, and mental health). Each
question was asked independently. The second was the 22-item Sino-
Nasal Outcome Test (SNOT-22), which is a validated patient self-
reported measure,21 which encompasses all major symptoms in-
cluded in the diagnostic criteria set in the European Position Paper on
Rhinosinusitis and Nasal Polyps 2012 for CRS.9 Furthermore, to eval-
uate the severity of symptoms, all the subjects filled out the self-
reported visual analog scale (VAS) questionnaire, which included
questions on nasal obstruction and on nasal discharge. In brief, it
consists of a continuous scale made of a 10-cm horizontal line an-
chored by two verbal descriptors, one for each symptom extreme (0,
not troublesome; 10 cm, most troublesome imaginable). Based on the
average severity of the VAS scores, the degree of severity of the
disease was classified into three categories: mild, moderate, and
severe (mild, VAS score  0–3; moderate, VAS score  4–7; and
severe, VAS score  8–10). A VAS of 5 indicated poor QoL.9
QoL tools, as well as nasal endoscopy, was administered at baseline
before treatments (T0) and 3 months after therapies (T1). Continuous
baseline characteristics were described as mean and standard devia-
tion. Differences between the groups were tested with the Student’s
t-test. A p value of 0.05 was considered statistically significant.
RESULTS
At baseline, no statistically significant differences were observed
between the groups in the clinical, endoscopic, imaging, and QoL
tools, and the VAS score showed a moderate-to-severe degree of
disease (Table 1). In particular, at T0, all the diagnostic tools showed
a greater degree of severity in CRSwNP with NARES than in AR
(Table 2). After treatments, the Lund-Kennedy, SF-36, SNOT-22, and
VAS scores were statistically significant (p  0.05) in both investiga-
tional and control groups, but a more significant improvement in
clinical and instrumental parameters (p 0.05) was observed in favor
of group I (Table 3). In the same way, a more significant improvement
(p  0.05) was observed in favor of subjects with AR than in subjects
with NARES in both the investigational and control groups (Table 4).
No patients reported adverse reactions or complications.
DISCUSSION
Oral and intranasal corticosteroids are the most commonly used
medications for CRS.9 According to the current state of knowledge,
topical corticosteroids are used in upper airway diseases with differ-
ent inflammatory mechanisms, such as CRSwNP and CRS without
nasal polyposis.22 Unquestionable advantages of topical corticoste-
Table 1 Baseline
Group Age mean  SD Score mean  SD
LK LM SF-36 SNOT-22 VASo VASd
I 56.9  5.6 8.7 1.6 15.5 5.4 56.9 2.9 49.4  3.7 8.5  1.0 8.5  1.0
II 56.8 4.4 8.6 1.9 16.2 4.2 57.4 4.8 49.0  3.6 8.5  1.1 8.3  1.2
p Value 0.8 0.9423 0.5793 0.6033 0.6791 0.9717 0.3739
SD  Standard deviation; LK  Lund-Kennedy; LM  Lund-Mackay; SF-36  Short Form 36; SNOT-22  22-item Sino-Nasal Outcome Test; VASo 
visual analog scale, nasal obstruction; VASd  visual analog scale, nasal discharge.
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roids are their strong anti-inflammatory local action, with little impact
on general health, and few adverse effects. In particular, their anti-
inflammatory effect can reduce mucosal edema and decrease the size
of nasal polyps.22 The main mechanism of action of corticosteroids is
the binding to the intracellular corticosteroid receptors and their
impact on nuclear cytoplasmic transcriptional factors. Corticosteroids
suppress gene expression of factors responsible for generating and
supporting inflammatory processes, proinflammatory cytokines and
chemokine production, and adhesive molecules expression. It seems
that corticosteroids also have additional mechanisms of action, which
do not involve intracellular receptors and do lead to inhibition of
early and late phase of allergic reaction.22
Topical nasal corticosteroids are of proven efficacy for treating
CRSwNP; however, they may be responsible for several adverse
effects, among which the most common are epistaxis, dry nose, nasal
burning, and nasal irritation.9,23 These conditions are commonly tol-
erated by the patient, but the prolonged use of topical corticosteroids
may compromise not only the patient’s QoL but also the compliance
to therapy. Thus, although many studies have investigated the use of
different topical agents to improve symptoms related to CRSwNP,9
there is still an unmet medical need for an effective therapy that can
be administered for a long time without adverse effects.
Recently, SH treatment has been shown to stimulate the mucocili-
ary clearance, thereby improving wound healing and repairing of
mucosal surfaces.1,3,4,12,14,15 Additional evidence has also reported the
effectiveness of 9 mg of nebulized high-molecular-weight SH in the
treatment of sinonasal clinical, endoscopic, and psychologic parame-
ters in patients undergoing functional endoscopic sinus surgery for
sinonasal remodeling.1,3,4,12,14,15 Furthermore, SH, in association with
intranasal corticosteroid and systemic antihistamine, reduces the neu-
trophil count shown on nasal cytology in patients with AR and
non-AR, and improves several clinical and endoscopic parameters.13
In our study we evaluated the effect of SH supplement to standard
intranasal corticosteroid in the treatment of CRSwNP with AR and
NARES, not only in terms of clinical outcomes but also in terms of
QoL. Indeed, we strongly believe that patients’ perspective on treat-
ment outcomes is a crucial element for improving high-quality care.
For these reasons, in this study, the impact of treatments was deter-
mined by using endoscopic parameters and validated QoL question-
naires such as SF-36, SNOT-22, and VAS. At baseline, no statistically
Table 2 Degree of severity between AR and NARES at T0
T0 Score mean  SD
LK LM SF-36 SNOT-22 VASo VASd
AR 8.3  1.8 15.4 4.1 59.0 2.3 47.8 3.2 8.2 1.1 8.1 1.2
NARES 9.6  1.5 18.6 3.5 53.8 4.2 50.8 3.1 9.0 0.9 8.9 0.8
p Value 0.05 0.05 0.05 0.05 0.05 0.05
CRSwNP Chronic rhinosinusitis with nasal polyposis; NARES non–allergic-eosinophilic rhinitis; AR allergic rhinitis; SD standard deviation; LK
Lund-Kennedy; LM Lund-Mackay; SF-36 Short Form 36; SNOT-22 22-item Sino-Nasal Outcome Test; VASo visual analog scale, nasal obstruction;
VASd  visual analog scale, nasal discharge.
Table 3 Results after treatment between group I and II
Score mean  SD
LK SF-36 SNOT-22 VASo VASd
Group I
T0 8.7  1.6 56.9  2.9 49.4  3.7 8.5  1.0 8.5  1.0
T1 5.1  1.6 63.6  2.0 44.9  3.7 5.8  1.1 5.6  1.0
p Value 0.05 0.05 0.05 0.05 0.05
Group II
T0 8.6  1.9 57.4  4.8 49.0  3.6 8.5  1.1 8.3  1.2
T1 6.4  2.1 60.5  5.4 47.4  3.8 7.2  1.0 7.3  1.1
p Value 0.05 0.05 0.05 0.05 0.05
T1 results between group I and group II
T1 group I 5.1  1.6 63.6  2.0 44.9  3.7 5.8  1.1 5.6  1.0
T1 group II 6.4  2.1 60.5  5.4 47.4  3.8 7.2  1.0 7.3  1.1
p Value 0.05 0.05 0.05 0.05 0.05
LK Lund-Kennedy; SF-36 Short Form 36; SNOT-22 22-item Sino-Nasal Outcome Test; VAS visual analog scale; VASo visual analog scale, nasal
obstruction; VASd  visual analog scale, nasal discharge.
Table 4 Results after treatment between AR and NARES
AR NARES p Value
Group I, mean (SD)
LK 4.4 1.2 6.7  1.3 0.05
SF-36 64.3 1.4 60.3  2.7 0.05
SNOT-22 43.7 2.9 45.2  3.8 0.05
VASo 5.5 1.0 6.3  1.1 0.05
VASd 5.6 1.0 5.3  1.0 0.05
Group II, mean (SD)
LK 5.4 1.7 8.3  1.4 0.05
SF-36 62.4 3.4 57.2  4.9 0.05
SNOT-22 45.9 3.7 48.4  2.7 0.05
VASo 7.1 1.0 7.7  0.9 0.05
VASd 6.8 1.1 8.0  0.9 0.05
AR  Allergic rhinitis; NARES  non–allergic-eosinophilic rhinitis; SD 
standard deviation; LK  Lund-Kennedy; SF-36  Short Form 36; SNOT-
22  22-item Sino-Nasal Outcome Test; VASo  visual analog scale, nasal
obstruction; VASd  visual analog scale, nasal discharge.
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significant differences were observed between groups I and II in the
clinical, endoscopic, imaging, and QoL tools, and the VAS score
showed a moderate-to-severe degree of disease (Table 1). In particu-
lar, at T0, all diagnostic tools showed a greater degree of severity in
CRSwNP with NARES than in AR (Table 2). After treatments, the
Lund-Kennedy, SF-36, SNOT-22, and VAS scores were statistically
significant (p  0.05) in both investigational and control groups, but
a more significant improvement in clinical and instrumental param-
eters (p  0.05) was observed in favor of group I (Table 3). This is not
surprising because the control arm was not treated with placebo but
with topical corticosteroids and saline solution that per se are thera-
peutic options. However, these results require additional studies to
evaluate the use of different therapeutic protocols in which the cor-
ticosteroids in association with SH could be used for shorter periods
and/or at lower doses than that used in the present study.
In the same way, a more significant improvement (p  0.05) was
observed in favor of subjects with AR than in the subjects with
NARES, in both investigational and control groups (Table 4). This
finding is in accordance with previous studies in which, although
both patients with AR and those with non-AR had good steroid
response, the patients with non–allergic phenotypes had less im-
provement than the patients with AR.24 Our findings demonstrated
that both therapeutic protocols (topical corticosteroids plus SH and
saline solution, and topical corticosteroids and saline solution) are
effective in the treatment of CRSwNP, but an SH supplement to
standard corticosteroids seems to enhance their efficacy with the
perspective of reducing the corticosteroid dosage, the duration of
topical therapy, and, as a consequence, the onset of the most common
drug-related events, such as epistaxis, dry nose, nasal burning, and
irritation. It remains to understand whether the therapeutic enhance-
ment operated by SH can prolong the well-being and the therapy-free
periods. Hence, this could be a future research project.
CONCLUSION
Analysis of our data indicated that SH supplement to standard
corticosteroid seems to play an important role in improving the
severity of symptoms and the endoscopic appearance and discomfort
associated with CRSwNP. This effect seems to be strongest in patients
with AR associated with CRSwNP. In addition, the supplement of SH
may significantly enhance the QoL, both in terms of the general health
status (SF-36) and in terms of the specific sinonasal status (SNOT-22).
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